<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402595</url>
  </required_header>
  <id_info>
    <org_study_id>15-AVP-786-103</org_study_id>
    <nct_id>NCT02402595</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts</brief_title>
  <acronym>DDI</acronym>
  <official_title>A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, Drug Interaction Study Between AVP-923 and Itraconazole, and Between AVP-786 and Itraconazole in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avanir Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avanir Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor,
      itraconazole, on the steady-state PK of AVP-923 and AVP-786.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, single-center, randomized, double-blind, double-dummy drug interaction study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma concentration of AVP-923 after dosing in combination with itraconazole</measure>
    <time_frame>16 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma concentration of AVP-786 after dosing in combination with itraconazole</measure>
    <time_frame>16 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) for AVP-923 and itraconazole</measure>
    <time_frame>16 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) for AVP-786 and itraconazole</measure>
    <time_frame>16 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1 - Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 1 - Period 2 (after 3-week washout)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 - Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 - Period 2 (after 3-week washout)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVP-923</intervention_name>
    <arm_group_label>Sequence 1 - Period 1</arm_group_label>
    <arm_group_label>Sequence 2 - Period 2 (after 3-week washout)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVP-786</intervention_name>
    <arm_group_label>Sequence 1 - Period 2 (after 3-week washout)</arm_group_label>
    <arm_group_label>Sequence 2 - Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <arm_group_label>Sequence 1 - Period 1</arm_group_label>
    <arm_group_label>Sequence 1 - Period 2 (after 3-week washout)</arm_group_label>
    <arm_group_label>Sequence 2 - Period 1</arm_group_label>
    <arm_group_label>Sequence 2 - Period 2 (after 3-week washout)</arm_group_label>
    <other_name>Sporanex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and females, 18 to 55 years of age

          -  Body Mass Index (BMI) ≥19 and ≤30 kg/m2 (for both males and females)

        Exclusion Criteria:

          -  History or presence of significant disease

          -  History of substance abuse or dependence (except caffeine), or treatment for substance
             use disorder(s) within the year prior to screening or within 6 months for nicotine
             including e-cigarettes

          -  Use of any tobacco-containing or nicotine-containing products within 6 months prior to
             the first dose

          -  Use of any prescription or the over-the-counter medications within 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Kankam, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vince and Associates Clinical Research Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>deuterated dextromethorphan</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>dextromethorphan with quinidine</keyword>
  <keyword>deuterated dextromethorphan with quinidine</keyword>
  <keyword>itraconazole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

